Literature DB >> 23729727

A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?

Nelson Leung1, Siobhan V Glavey, Shaji Kumar, Angela Dispenzieri, Francis K Buadi, David Dingli, Martha Q Lacy, Suzanne R Hayman, John A Lust, Stephen J Russell, Steven R Zeldenrust, S Vincent Rajkumar, Morie A Gertz.   

Abstract

Organ response correlates with overall survival in patients with immunoglobulin light chain amyloidosis and is the goal of treatment. This study evaluates the current renal response criteria and their ability to predict overall survival. Patients with immunoglobulin light chain amyloidosis who underwent autologous stem cell transplantation between 1995 and 2010 were recruited. Eligibility criteria included >1 g/dL of proteinuria, dialysis independence at baseline and within the first year of autologous stem cell transplantation, and a minimum follow-up of 1 year. Responses were assessed by the best values after autologous stem cell transplantation. The difference between involved and uninvolved serum free light chain levels was used to determine hematologic response. Increases in serum creatinine were calculated from the highest creatinine after autologous stem cell transplantation. Inclusion and exclusion criteria were met by 141 patients. These patients had a median follow-up of 52 months. Superior overall survival was observed in patients with a >75% reduction in proteinuria and those who had a >95% reduction had additional benefits. The overall survival of patients with >50% to ≤75% proteinuria was similar to that of patients with ≤50% reduction. A rise in serum creatinine >25% was not associated with a poorer outcome in patients with a >75% reduction in proteinuria. Deeper hematologic responses were associated with higher rates of proteinuria reduction. These results suggest that further evaluation of the current renal response criteria is needed. In particular, discrimination of the renal response into complete and partial categories and modification of the serum creatinine requirement seem justified.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23729727      PMCID: PMC3669457          DOI: 10.3324/haematol.2012.079210

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  12 in total

Review 1.  Molecular mechanisms of amyloidosis.

Authors:  Giampaolo Merlini; Vittorio Bellotti
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

2.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Joseph P McConnell; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; William J Hogan; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Christopher G A McGregor; Allan S Jaffe
Journal:  Blood       Date:  2004-03-25       Impact factor: 22.113

3.  The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

Authors:  Giovanni Palladini; Alessandra Barassi; Catherine Klersy; Rosana Pacciolla; Paolo Milani; Gabriele Sarais; Stefano Perlini; Riccardo Albertini; Paola Russo; Andrea Foli; Letizia Zenone Bragotti; Laura Obici; Remigio Moratti; Gian Vico Melzi d'Eril; Giampaolo Merlini
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

4.  Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

Authors:  V Sanchorawala; D C Seldin; B Magnani; M Skinner; D G Wright
Journal:  Bone Marrow Transplant       Date:  2005-10       Impact factor: 5.483

Review 5.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Authors:  Morie A Gertz; Ray Comenzo; Rodney H Falk; Jean Paul Fermand; Bouke P Hazenberg; Philip N Hawkins; Giampaolo Merlini; Philippe Moreau; Pierre Ronco; Vaishali Sanchorawala; Orhan Sezer; Alan Solomon; Giles Grateau
Journal:  Am J Hematol       Date:  2005-08       Impact factor: 10.047

6.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

7.  Outcome in renal Al amyloidosis after chemotherapy.

Authors:  Jennifer H Pinney; Helen J Lachmann; Loveleen Bansi; Ashutosh D Wechalekar; Janet A Gilbertson; Dorota Rowczenio; Prayman T Sattianayagam; Simon D J Gibbs; Emanuela Orlandi; Nancy L Wassef; Arthur R Bradwell; Philip N Hawkins; Julian D Gillmore
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

8.  Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.

Authors:  Nelson Leung; Tessa R Leung; Stephen S Cha; Angela Dispenzieri; Martha Q Lacy; Morie A Gertz
Journal:  Blood       Date:  2005-07-21       Impact factor: 22.113

Review 9.  How I treat amyloidosis.

Authors:  Raymond L Comenzo
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

10.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Philip R Greipp; Thomas E Witzig; John A Lust; S Vincent Rajkumar; Rafael Fonseca; Steven R Zeldenrust; Christopher G A McGregor; Allan S Jaffe
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

View more
  10 in total

1.  Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement.

Authors:  A M Cornelison; R M Saliba; A Afrough; Y Dinh; Y Nieto; Q Bashir; N Shah; S Parmar; C Hosing; U Popat; E Shpall; R Champlin; M H Qazilbash
Journal:  Bone Marrow Transplant       Date:  2015-10-19       Impact factor: 5.483

2.  Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Authors:  Giovanni Palladini; Paolo Milani; Andrea Foli; Laura Obici; Francesca Lavatelli; Mario Nuvolone; Riccardo Caccialanza; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

3.  A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.

Authors:  Nelson Leung; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2016-03-18       Impact factor: 8.237

4.  Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.

Authors:  E Kastritis; M Gavriatopoulou; M Roussou; D Fotiou; D C Ziogas; M Migkou; E Eleutherakis-Papaiakovou; I Panagiotidis; N Kanellias; E Psimenou; E Papadopoulou; C Pamboucas; E Manios; H Gakiopoulou; A Ntalianis; A Tasidou; S Giannouli; E Terpos; M A Dimopoulos
Journal:  Blood Cancer J       Date:  2017-06-16       Impact factor: 11.037

Review 5.  Novel Therapies in Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Kidney Int Rep       Date:  2017-11-28

6.  [The consensus of the diagnosis and treatment of primary light chain amyloidosis in China (2016 version)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-09-14

7.  [Primary light chain amyloidosis onset with acquired FX deficiency: a case report and literature review].

Authors:  C Wei; J Feng; T N Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

8.  Pathologic light chain amyloidosis oligomer detection in urinary extracellular vesicles as a diagnostic tool for response and progression of disease.

Authors:  Shawna A Cooper; Christopher J Dick; Pinaki Misra; Nelson Leung; Carrie A Schinstock; Marina Ramirez-Alvarado
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

9.  Estimation of Daily Proteinuria in Patients with Amyloidosis by Using the Protein-To-Creatinine ratio in Random Urine Samples.

Authors:  Giampaolo Talamo; A Mir Muhammad; Manoj K Pandey; Junjia Zhu; Michael H Creer; Jozef Malysz
Journal:  Rare Tumors       Date:  2015-02-18

10.  Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ Involvement.

Authors:  Jack T Seki; Naoko Sakurai; Vishal Kukreti
Journal:  J Clin Med Res       Date:  2015-08-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.